Evidence map›Paper›PMID 37273472›Full record

ArticleStructural heart : the journal of the Heart Team2022

Postdischarge-to-30-Day Mortality Among Patients Receiving MitraClip: A Systematic Review and Meta-Analysis.

Beni R Verma, Shashank Shekhar, Toshiaki Isogai, Raghuram Chava, Pejman Raeisi-Giglou, Agam Bansal, Shameer Khubber, Bryce Montane, Prashansha Vaidya, Simrat Kaur and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Structural heart : the journal of the Heart Team, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Beni R VermaHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Shashank ShekharHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Toshiaki IsogaiHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Raghuram ChavaDepartment of Cardiology, Case Western MetroHealth Health System, Cleveland, Ohio, USA.
Pejman Raeisi-GiglouDepartment of Cardiology, Case Western MetroHealth Health System, Cleveland, Ohio, USA.
Agam BansalHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Shameer KhubberHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Bryce MontaneHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Prashansha VaidyaDepartment of Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
Simrat KaurHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Manpreet KaurHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Rhonda MiyasakaHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Serge C HarbHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Amar KrishnaswamyHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Samir R KapadiaHeart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Cleveland Clinic · USMetroHealth Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: MitraClip (MC) implantation is the recommended treatment for severe symptomatic mitral regurgitation in patients not responding to medical therapy and at prohibitive surgical risk. It is important to quantify immediate mortality during postdischarge-to-30-day period so as to improve the procedural outcomes. Hence, we aim to identify the incidence of postdischarge-to-30-day mortality and its associated predictors using the technique of meta-analysis. Methods: We searched Medline, Embase, and Cochrane CENTRAL databases from inception until July 3, 2019 for studies reporting mortality prior to discharge, at 30 days and 1 year after MC implantation. The primary outcome was postdischarge-to-30-day all-cause mortality. Results: Of 2394 references, 15 studies enrolling 7498 patients were included. Random effects analysis showed that all-cause cumulative inpatient, 30-day, and 1-year mortality was 2.40% (2.08, 2.77; Conclusions: Our meta-analysis reports an additional mortality of ∼2% immediately after MC implantation during the postdischarge-to-30-day period. Majority of deaths occurred due to cardiac causes. Pre-MC left ventricular ejection fraction, Log.Euroscore, Society of Thoracic Surgeons Predicted Risk of Mortality score, and prolonged ventilation were found to be its significant predictors. Further studies are needed to better understand the causes of this early mortality to maximize benefits of this important therapy.

Indexed as

Heart failureMitral valve diseaseMortalityPercutaneous valve therapyStructural heart disease intervention

Identifiers

PMID37273472
PMCPMC10236879
OpenAlexW4224443868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.